Novo Nordisk Total Non-Operating Income/Expense 2010-2024 | NVO

Novo Nordisk total non-operating income/expense for the twelve months ending September 30, 2024 was $0.129B, a 75.94% increase year-over-year.

  • Novo Nordisk annual total non-operating income/expense for 2023 was $0.305B, a 137.47% decline from 2022.
  • Novo Nordisk annual total non-operating income/expense for 2022 was $-0.814B, a 1273.13% decline from 2021.
  • Novo Nordisk annual total non-operating income/expense for 2021 was $0.069B, a 145.46% decline from 2020.

Novo Nordisk Total Non-Operating Income/Expense 2010-2024 | NVO

  • Novo Nordisk annual total non-operating income/expense for 2023 was $0.305B, a 137.47% decline from 2022.
  • Novo Nordisk annual total non-operating income/expense for 2022 was $-0.814B, a 1273.13% decline from 2021.
  • Novo Nordisk annual total non-operating income/expense for 2021 was $0.069B, a 145.46% decline from 2020.